Vistagen Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Vistagen Therapeutics, Inc. on September 10, 2026. The filing details the outcomes of three key proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on the following matters:
- Election of Directors: All four nominees were elected to the Board of Directors. Notable voting splits included Ann M. Cunningham and Shawn K. Singh, who received significant "Withheld" votes compared to other nominees.
- Executive Compensation (Say-on-Pay): Stockholders approved the non-binding advisory vote on executive compensation with a majority of votes cast.
- Auditor Ratification: Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2027.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies. It refers investors to the definitive proxy statement filed on July 31, 2026, for further details on the proposals.
Investor Verification Checklist
- Verify the specific reasons for the high "Withheld" vote counts for directors Ann M. Cunningham and Shawn K. Singh in the July 31, 2026 proxy statement.
- Review the definitive proxy statement for details on the executive compensation package approved in Proposal No. 2.
- Confirm the fiscal year-end date of March 31, 2027, for future financial reporting expectations.